News
Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty
With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and infants, Merck & Co. Inc. steps into a space of competition and regulatory shifts.
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...
Merck & Co., Inc. ( NYSE: MRK) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M. Davis - ...
When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...
Merck, which is evaluating the safety and efficacy of enlicitide for the treatment of adults with hyperlipidemia on lipid-lowering therapies, including at least a statin, said the Phase 3 studies met ...
Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...
Zacks Investment Research on MSN4h
Merck (MRK) Rises Higher Than Market: Key FactsThe most recent trading session ended with Merck (MRK) standing at $81.35, reflecting a +2.55% shift from the previouse trading day's closing. This move outpaced the S&P 500's daily gain of 0.55%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback